MDGL catalyst calendar

MADRIGAL PHARMACEUTICALS, INC.

Upcoming catalysts
8
Cash runway
15 months
Cash & investments
$839M
Phase 3 programs
4

MADRIGAL PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 29, 2026, a projected date rather than a confirmed one. There are 8 upcoming events on record.

Cash runway is approximately 15 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 13 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 29, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) Trial Milestone Phase 3
March 15, 2027 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Trial Milestone Phase 3
November 15, 2027 Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis Trial Milestone Phase 4
November 15, 2027 Resmetirom in Patients With MASH and HFpEF Trial Milestone Phase 1
January 15, 2028 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis Trial Milestone Phase 3
August 15, 2028 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH Trial Milestone Phase 2
July 15, 2029 Study of Resmetirom in Children and Adolescents With MASH Trial Milestone Phase 2

Track MDGL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MDGL in the tracker

Recent history

DateEventTypePhase
August 12, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
July 30, 2026 Quarterly results filed (8-K) Earnings —
June 17, 2026 8-K filed: Leadership change Corporate —
May 6, 2026 Quarterly results filed (8-K) Earnings —
April 28, 2026 8-K filed: Leadership change Corporate —
February 19, 2026 Quarterly results filed (8-K) Earnings —
January 30, 2026 8-K filed: Material agreement Corporate —
December 11, 2025 8-K filed: Leadership change Corporate —
November 4, 2025 Quarterly results filed (8-K) Earnings —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 30, 2025 8-K filed: Reg FD disclosure Filing —
July 22, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
May 1, 2025 Quarterly results filed (8-K) Earnings —
April 17, 2025 8-K filed: Leadership change Corporate —
September 16, 2024 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function Trial Milestone Phase 1
January 6, 2023 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients Trial Milestone Phase 3
August 4, 2021 Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Trial Milestone Phase 1
August 30, 2019 Drug Interaction Study of MGL-3196 With Clopidogrel Trial Milestone Phase 1
December 11, 2018 Drug Interaction Study of MGL-3196 With Pioglitazone Trial Milestone Phase 1
February 17, 2018 Bioavailability Study of MGL-3196 Tablets Compared to Capsules Trial Milestone Phase 1
January 15, 2018 Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Trial Milestone Phase 2
October 25, 2017 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
September 3, 2017 Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.